Extended Data Fig. 2: Evaluation of CB-839/AZA drug synergy in AML cell lines in vitro. | Nature Cancer

Extended Data Fig. 2: Evaluation of CB-839/AZA drug synergy in AML cell lines in vitro.

From: Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Extended Data Fig. 2

Representative graphs demonstrating synergistic effect of CB-839 and azacytidine (AZA) combination in AML cells. Cells were exposed to increasing doses of CB-839 and AZA alone or at constant drugs’ ratios for 5 days. Cell viability was determined by CellTiter-Glo luminescence assay. Combination index (CI) is the average ±SD of CIs at effective doses EC50, EC75, and EC90 calculated using CalcuSyn software. The CI < 1 = synergism; CI > 1 = antagonism (n = 4 technical replicates, mean ± SD).

Source data

Back to article page